Sweden Pharmaceuticals & Healthcare Report

Published 13 May 2015

  • 122 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Sweden Pharmaceuticals & Healthcare Report

BMI View: Private healthcare providers are to face an increasingly challenging business environment in Sweden. In October 2014, the newly elected government reached an agreement on initiatives aimed at imposing further restrictions on private companies engaged in publicly funded healthcare, care and educational services - and, as part of that limit, their right to distribute profits. This may result in reduced private investment in the country's healthcare sector and may potentially result in diminished innovation as well as capacity problems. In April 2015, the first regional council ordered its officials to find ways to limit the profits private companies can reap from running publicly-funded health services.

Headline Expenditure Projections

  • Pharmaceuticals: SEK36.41bn (USD5.31bn) in 2014 to SEK36.62bn (USD4.43bn) in 2015; +0.57% in local currency terms and -16.6% in US dollar terms.

  • Healthcare: SEK362.41bn (USD52.81bn) in 2014 to SEK371.80bn (USD44.94bn) in2015; +2.6% in local currency terms and -14.9% in US dollar terms.

Risk/Reward Index: We continue to view Sweden as a moderately attractive regional market. On the positive side, factors such as the country's high per capita incomes and strong regulatory foundations will continue to promote per capita spending on pharmaceuticals and healthcare in general. However, the downward pressure on pharmaceutical prices will continue to be acutely felt in this small market of fewer than 10mn people.

Key Trends And Developments

  • In April 2015, Swedish pharmaceutical firm Swedish Orphan Biovitrum (Sobi) received a preliminary takeover offer from an unnamed suitor, according to Head of Communications Oskar Bosson. A suitor for Sobi would most likely be interested in acquiring the firm due to its presence in the haemophilia drug market, where the company and Biogen have developed two new drugs under a partnership deal. Analysts noted that Biogen or Pfizer were the two most likely buyers but other big pharmaceutical...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2011-2019)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2011-2019)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2011-2019)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2011-2019)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2011-2019)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2011-2019)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2011-2019)
25
OTC Medicine Market Forecast
26
Table: OTC Sales by Therapeutic Group At Retail Prices, 2009-2010 (SEKmn)
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2011-2019)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Sweden 2013-2019)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2013-2019)
31
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
32
Economic Analysis
32
Policy Shifts: Two Positive, One Negative
35
GDP By Expenditure
37
Table: GDP By Expenditure (Sweden 2012-2019)
40
Industry Risk Reward Ratings
41
Western Europe Risk/Reward Index
41
Sweden Risk/Reward Index
45
Rewards
45
Risks
46
Market Overview
48
Industry Trends And Developments
49
Epidemiology
49
Healthcare Sector
51
Healthcare Financing
53
Table: Healthcare Resources (Sweden 2009-2014)
54
Table: Healthcare Personnel (Sweden 2009-2014)
55
Table: Healthcare Activity (Sweden 2009-2014)
55
Research And Development
55
Table: Drug Development Member Companies of SwedenBIO, 2011
56
Clinical Trials
57
Regulatory Development
61
Regulatory Regime
61
Intellectual Property Regime
62
Pricing Regime
63
Recent Pricing Developments
64
Reimbursement Regime
65
Competitive Landscape
67
Pharmaceutical Industry
67
Pharmaceuticals Manufacturing Sector
68
Pharmaceutical Industry Developments
69
Pharmaceutical Distribution
71
Pharmaceutical Retail Sector
74
Table: Drug Retail Establishments by Type, 2006-2010
75
Company Profile
78
Meda
78
Swedish Orphan Biovitrum (SOBI)
82
Medivir
88
GlaxoSmithKline
92
Pfizer
95
Novartis
98
Sanofi
101
Merck & Co
103
AstraZeneca
105
Demographic Forecast
110
Table: Population Headline Indicators (Sweden 1990-2025)
111
Table: Key Population Ratios (Sweden 1990-2025)
111
Table: Urban/Rural Population And Life Expectancy (Sweden 1990-2025)
112
Table: Population By Age Group (Sweden 1990-2025)
112
Table: Population By Age Group % (Sweden 1990-2025)
113
Glossary
115
Methodology
117
Pharmaceutical Expenditure Forecast Model
117
Healthcare Expenditure Forecast Model
117
Notes On Methodology
118
Risk/Reward Index Methodology
119
Index Overview
120
Table: Pharmaceutical Risk/Reward Index Indicators
120
Indicator Weightings
121

The Sweden Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Sweden Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Sweden pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Sweden, to test other views - a key input for successful budgeting and strategic business planning in the Swedish pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Swedish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Sweden.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%